Choledocholithiasis: Who Goes Straight to ERCP, Who Gets MRCP or EUS First

Bottom line

Initial workup and risk stratification

• Apply the ASGE 2019 stratification: HIGH = common bile duct stone on imaging, clinical ascending cholangitis, or total bilirubin > 4 mg/dL plus a dilated duct → straight to ERCP. INTERMEDIATE = abnormal liver tests, a dilated duct (> 6 mm with the gallbladder in situ), or age over 55 without high-risk features → EUS or MRCP first. LOW = normal liver tests and a non-dilated duct → cholecystectomy without further duct imaging.
• For intermediate risk, obtain MRCP or EUS — whichever is available fastest, ideally within 24 hours — to confirm or exclude a retained stone before committing to ERCP. EUS has the edge for small (< 5 mm) stones and sludge and allows same-session ERCP if a stone is found; use EUS when MRI is contraindicated by incompatible implants or severe claustrophobia.
• Labs and support: CBC, CMP with liver tests trended every 12–24 hours, lipase (to exclude gallstone pancreatitis), INR, and blood cultures for any fever or rigors. If bilirubin and liver tests fall substantially on serial testing, spontaneous stone passage is likely and the patient may reclassify toward low risk — proceed to cholecystectomy with an intraoperative cholangiogram instead.

Acute management

• NPO or clear liquids, IV isotonic fluids, analgesia (NSAID or opioid), and antiemetics; no antibiotics for isolated choledocholithiasis without cholangitis.
• Surgery and GI consultation on admission, planning for same-admission duct clearance and cholecystectomy.
• If MRCP or EUS shows a stone → ERCP with sphincterotomy and stone extraction, typically within 24–72 hours in a stable patient. Alternatively, laparoscopic cholecystectomy with intraoperative cholangiogram and laparoscopic common bile duct exploration is a reasonable single-step strategy associated with shorter length of stay than ERCP followed by surgery.
• If MRCP or EUS is negative → do not perform ERCP; proceed to laparoscopic cholecystectomy this admission with an intraoperative cholangiogram.
• Recognize cholangitis (fever or rigors, or elevated WBC or CRP, plus cholestasis, plus imaging evidence of biliary obstruction). If present → blood cultures, IV antibiotics (ceftriaxone 2 g IV daily plus metronidazole 500 mg IV every 8 hours for community-acquired non-severe disease; piperacillin-tazobactam 4.5 g IV every 6–8 hours for severe, healthcare-associated, or post-instrumentation cases), and biliary drainage within about 24 hours, sooner if septic or refractory.
• Gallstone pancreatitis alone is no longer an ASGE high-risk criterion. In pancreatitis without cholangitis or persistent obstruction, urgent ERCP within 48 hours is not recommended — manage with fluids and early cholecystectomy.

Inpatient and longitudinal management

• Perform laparoscopic cholecystectomy during the same admission after duct clearance — ideally within 72 hours of ERCP and before discharge — to prevent recurrent biliary events; interval outpatient cholecystectomy carries a substantial readmission rate.
• Confirm biochemical resolution: liver tests and bilirubin should trend down after decompression. Persistent or rising cholestasis suggests a retained stone, stricture, or malignancy and warrants repeat imaging or ERCP.
• In a poor surgical candidate, ERCP with sphincterotomy alone is an acceptable definitive strategy, with counseling about recurrent biliary events.
• Standard inpatient care: VTE prophylaxis, resumption of diet after procedures, and monitoring for delayed post-sphincterotomy bleeding.

Monitoring and disposition

• A routine floor bed with vitals every 4–8 hours and daily liver tests and CBC; telemetry is not required for a stable presentation.
• After ERCP: monitor pain, check lipase if symptomatic, follow hemoglobin for post-sphincterotomy bleeding, and advance diet as tolerated.
• Discharge criteria: duct cleared, cholecystectomy completed (or a definitive plan if nonoperative), tolerating a diet, pain controlled, bilirubin and alkaline phosphatase trending down, and afebrile.
• Follow-up with surgery in 2–4 weeks and with GI if there was a sphincterotomy or retained-stone concern; return for fever, jaundice, or recurrent right upper quadrant pain.

Escalate care if

• Fever, rigors, hypotension, or altered mentation develop — treat as acute cholangitis with blood cultures, broad-spectrum IV antibiotics, fluids, and urgent ERCP drainage within about 24 hours (emergently in septic shock); ICU for vasopressor need.
• ERCP fails or is not anatomically feasible — percutaneous transhepatic or EUS-guided biliary drainage.
• Post-ERCP abdominal pain with a rising lipase — evaluate for post-ERCP pancreatitis; consider perforation or bleeding if pain is severe or hemoglobin falls, with CT as indicated.
• No stone is found but cholestasis persists or worsens — pursue MRCP or CT and consider malignancy, primary sclerosing cholangitis, or drug-induced cholestasis.
• Bilirubin rises above 4 mg/dL with a dilated duct, or a stone becomes visible on imaging — the patient reclassifies as high risk; proceed directly to ERCP.

Duration

Antibiotics are given only for cholangitis, typically 4–7 days total and often about 4 days after adequate biliary drainage with clinical response, longer for gram-positive bacteremia.

Caveats

• ERCP is the treatment for a confirmed or highly likely duct stone, not a screening test: it carries a 5–7% adverse-event risk (pancreatitis, bleeding, perforation, cholangitis), so in intermediate-risk patients let MRCP or EUS answer whether a stone is present before committing to it.
• Correct coagulopathy and plan antiplatelet and anticoagulant timing before sphincterotomy.
• ASGE and ESGE differ slightly in high-risk definitions: ESGE requires a visualized stone or cholangitis, while ASGE additionally counts bilirubin > 4 mg/dL with duct dilation. Both route intermediate-risk patients to EUS or MRCP.
• MRCP is contraindicated with incompatible implants or severe claustrophobia — use EUS instead.

References

1. ASGE guideline on the role of endoscopy in the evaluation and management of choledocholithiasis. Gastrointestinal Endoscopy. (2019) · Primary guideline“It appears that EUS and MRCP result in cost-saving by avoiding the expense and adverse events of ERCP.”
2. ASGE guideline on the role of endoscopy in the evaluation and management of choledocholithiasis (journal abstract). (2019) · Primary guideline“Identifying patients likely to have CDL is an important clinical dilemma because endoscopic retrograde cholangiopancreatography (ERCP), carries a 5-7% risk of adverse events.”
3. Performance of Diagnostic Guidelines in the Evaluation of Choledocholithiasis in Patients With Acute Biliary Presentation: A Systematic Review and Meta-Analysis. (2025) · Systematic review“All three guidelines recommend ERCP or laparoscopic treatment for CBDS for patients stratified as high risk, MRCP or EUS for patients stratified as intermediate risk, and no additional workup prior to cholecystectomy for patients stratified as low risk.”
4. Evaluating the Revised American Society for Gastrointestinal Endoscopy Guidelines for Common Bile Duct Stone Diagnosis. (2021) · Primary source“Under the revised guidelines, 86 (32%) patients met the criteria for high risk, of whom 83% had choledocholithiasis.”
5. Unnecessary ERCPs: Is Spontaneous Stone Passage the Sole Determinant? (2026) · Narrative review“ESGE considers high-risk patients as those with either a confirmed stone on initial imaging or features of acute cholangitis, whereas ASGE additionally includes a total bilirubin level exceeding 4 mg/dL combined with common bile duct dilation as a high-risk criterion.”